Relapsing Polychondritis


Article Author:
William Gossman
Krati Chauhan


Article Editor:
Andrew Hanna


Editors In Chief:
Jasleen Jhajj
Cliff Caudill


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Frank Smeeks
Kristina Soman-Faulkner
Trevor Nezwek
Radia Jamil
Patrick Le
Sobhan Daneshfar
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
7/11/2019 11:24:12 PM

Introduction

Relapsing polychondritis (RP) is a rare autoimmune condition which presents as recurrent episodes of cartilaginous inflammation of the auricular, nasal and tracheal cartilage. Jaksh-Wartenhorst described the first case in 1923. A 32-year-old patient presented with fever, pain, and swelling of the ears and later developed stenosis of external auditory canal and saddle nose deformity. A biopsy of the nasal cartilage showed the absence of cartilage. The term relapsing polychondritis was coined by Pearson and his coworkers in 1960. They recognized it as an inflammatory condition of the and noncartilaginous structures.[1][2][3]

Etiology

The etiology of relapsing polychondritis is not known. It is suggested to result in a genetically predisposed individual on exposure to a triggering factor. The triggering factor may be an infectious agent, chemical, toxic exposure, or direct trauma. Relapsing polychondritis cases have been reported after trauma to pinna. A possible explanation includes cryptogenic antigenic release after trauma and recognition antigen by the immune system. Genetic studies have shown an association between HLA-DR4 antigen and relapsing polychondritis.[4][5]

Epidemiology

It is a rare disease, more common in Caucasians; prevalence is 4.5 cases/million. The peak age at onset is between 40 years to 50 years, though it can occur at any age. It occurs with equal frequency in both sexes and all racial groups. Over 30% of cases are associated with existing autoimmune condition or hematologic condition. [6][7]

Pathophysiology

Relapsing polychondritis primarily involves cartilaginous structures, suggesting immune mechanism are acting against proteoglycan the main constituent of cartilage. Circulating and tissue-specific antibodies against collagen type II, IX and XI are shown in patients with relapsing polychondritis. In addition to humoral immunity, cellular immunity helps in maintaining cartilage inflammation. CD4+ cell secretes cytokines like interelukin-8, macrophage inflammatory protein 1β, monocyte chemoattractant protein one which leads to recruitment of monocyte and macrophages. Macrophage release proteolytic enzymes, metalloproteinase (MMP-3), cathepsin L and K which leads to the destruction of cartilage. In early stages of the disease there is polymorphic inflammatory cell infiltration, later there is chondrocyte apoptosis, focal calcification, and fibrosis of the cartilage.[8]

History and Physical

Clinical spectrum of relapsing polychondritis is variable and varies with duration of the disease and disease severity. Auricular involvement is present in 90% of the cases, and inflammation is restricted to the cartilaginous portion of the ear with sparing of the ear lobes. Patients most frequently present with discoloration of the ear and pain. Articular involvement is the second most common manifestation present in 50% to 75% of patients. Wrist, metacarpophalangeal, proximal interphalangeal joints are commonly involved. Ocular manifestation occurs in 20% to 60% of relapsing polychondritis patients and involves episcleritis, scleritis, keratitis, and uveitis. Nasal chondritis occurs in about 25% of cases. Inflammation of the cartilaginous rings around trachea and bronchi results in the collapse of these airways (tracheobronchomalacia). Patient presents with a cough, hoarseness of voice, wheezing. Respiratory compromise is the most frequent cause of death in these patients.

Evaluation

Diagnosis of relapsing polychondritis is primarily based on a combination of clinical features, radiology, and biopsy of a cartilaginous site. It is guided by a set of clinical criteria suggested by McAdams et al. [9]  [10]Three of out of six criteria are required to make the diagnosis. These include:

  1. Recurrent chondritis of both auricles
  2. Nonerosive inflammatory arthritis
  3. Chondritis of nasal cartilages
  4. Inflammation of ocular structures: conjunctivitis/keratitis/scleritis/uveitis
  5. Chondritis of respiratory tract: Laryngeal, tracheal cartilage
  6. Cochlear or vestibular damage: Neurosensory hearing loss/tinnitus/vertigo

Any patient suspecting of having relapsing polychondritis should have a dynamic exploratory CT scan to evaluate for airway involvement. CT scans show functional airway abnormalities such as air trapping and collapse. It can also show thickening of the airway wall and luminal narrowing. Pulmonary function testing is done to evaluate for airway trapping. Pulmonary function test should be done to evaluate for lung volumes. PET-CT is a new diagnostic modality which helps in early disease recognition and provides a site for targeted biopsy.

Biopsy of auricular cartilage is performed to confirm the diagnosis of polychondritis. When relapsing polychondritis is associated with other Rheumatic diseases, positive serologic tests for rheumatoid factor, the anti-nuclear antibody may be seen. Complement levels are usually normal in patients with relapsing polychondritis. A non-erosive process of juxta-articular osteopenia and uniform, joint space narrowing characterizes arthropathy of relapsing polychondritis. Anti-type II collagen antibody tests are not routinely available, and hen these tests are done, these antibodies are not present in all the cases. There are no lab markers to assess for ongoing cartilage damage.

Treatment / Management

Due to the rarity of the disease, there are no there is no standardized treatment approach, and the treatment is guided by the clinical presentation and the severity of the disease.[2][11]

For patients presenting with auricular, nasal or articular involvement but no systemic involvement, anti-inflammatory medications, colchicine or dapsone is recommended. Low-dose glucocorticoid therapy is often required.

For patients with large airway involvement (laryngeal or tracheobronchial chondritis), abrupt onset of sensorineural hearing loss, ocular involvement IV methylprednisolone 1 gram for three days followed by oral prednisone 1 mg/kg along with immunosuppressive therapy is indicated. Most commonly used immunosuppressive agents include cyclophosphamide, methotrexate, azathioprine and cyclosporine. Cyclophosphamide is commonly used as the initial medication (1 mg/kg to 2 mg/kg) after remission is achieved it is switched to other less toxic immunosuppressive agents like azathioprine or methotrexate.

Biologics have been used in the treatment of relapsing polychondritis, most commonly used biologic is TNF inhibitor-Infliximab. Other biologics which have been tried with variable results include Adalimumab, etanercept, abatacept, tocilizumab. Data on Rituximab did not show success, and this agent is not recommended as the first line biologic agent.

Surgical intervention such as stenting, airway dilation, tracheostomy and laryngotracheal reconstruction are needed in case of airway collapse.

Differential Diagnosis

There is a presentation where the diagnosis of RP may be challenging. Nasal damage may occur as a result of drug abuse (cocaine), infections from fungi, tuberculosis, syphilis, granulomatous conditions like ANCA-associated vasculitis and lymphomatoid granulomatosis. Eye involvement similar to relapsing polychondritis may occur with rheumatoid arthritis, ANCA-associated vasculitis, polyarteritis nodosa, Behcet syndrome or Cogan syndrome.

Prognosis

The outcome of patients with relapsing polychondritis has improved in the recent years; survival has increased from 70% at five years to 91% at ten years. The more common clinical presentation is a relatively benign disease with respiratory failure due to airway collapse being the most common cause of death.

Pearls and Other Issues

 

 

Enhancing Healthcare Team Outcomes

RP is a very rare disorder that typically causes inflammation in cartilage bearing tissues like the ear, nose, larynx and the airways. The inflammatory episodes are recurrent and unpredictable. A concomitant autoimmune disease also occurs in more than 30% of patients. The diagnosis is not always easy because there are no specific tests. Even when diagnosed, the treatment is not standardized. The drug treatment is tailored to each patient and the cornerstone of therapy is the use of glucocorticoids. For patients with severe disease, other immunosuppressive are used including methotrexate and cyclophosphamide.[12][13] (level III)

Because these drugs have potent adverse effects, the role of the pharmacist and nurses are critical. Both these professionals play a role in educating the patient on the signs and symptoms of the adverse effects and also ensuring compliance with the medications. Recently newer biological agents have also been used to manage RP patients with varying results. However, prior to initiating treatment with these novel agents, the patient needs a thorough work up to ensure that he or she is fit to receive the therapy. Any patient with worsening of symptoms should be referred to the specialist. [14] (level III)

Outcomes

Patients with RP have frequent relapses and the quality of life is poor. The mortality rate of RP patients is twice that of the general population. Until randomized controlled studies are available, the treatment of RP will remain empirical and based on personal experience. For healthcare workers who have never treated such a patient, referral to a tertiary care center is recommended.[15] (level III)

 

 


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Relapsing Polychondritis - Questions

Take a quiz of the questions on this article.

Take Quiz
A 45-year-old white woman with a history of auricular chondritis and hearing loss presents to the clinic with an acute exacerbation of hoarseness, dyspnea, and tenderness over the thyroid cartilage. Treatment for this patient should include which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most common manifestation of relapsing polychondritis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Select the most common finding in relapsing polychondritis.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A young female with a recent history of uveitis presents with painful joints that are worse in the morning. Her erythrocyte sedimentation rate is 52. Select the feature that would help distinguish between relapsing polychondritis and rheumatoid arthritis.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A middle-aged woman develops painful swelling of her ears and nose, migratory polyarthritis, and iritis. Which of the following is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Relapsing Polychondritis - References

References

Borgia F,Giuffrida R,Guarneri F,Cannavò SP, Relapsing Polychondritis: An Updated Review. Biomedicines. 2018 Aug 2     [PubMed]
Zheutlin A,Schiopu E, Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature. Case reports in rheumatology. 2018     [PubMed]
Masuda N,Nishikawa R,Ueda T,Ogata N, Severe panuveitis with relapsing polychondritis. American journal of ophthalmology case reports. 2018 Sep     [PubMed]
Paravar T, Less common rheumatologic disorders: Current concepts of skin and systemic manifestations. Clinics in dermatology. 2018 Jul - Aug     [PubMed]
Krishnan Y,Grodzinsky AJ, Cartilage diseases. Matrix biology : journal of the International Society for Matrix Biology. 2018 May 24     [PubMed]
Leung KK,Edani S, Red-eared zebra diagnosis: Case of relapsing polychondritis. Canadian family physician Medecin de famille canadien. 2018 May     [PubMed]
Haslag-Minoff J,Regunath H, Relapsing Polychondritis. The New England journal of medicine. 2018 May 3     [PubMed]
Zampeli E,Moutsopoulos HM, Relapsing polychondritis: a diagnosis not to be missed. Rheumatology (Oxford, England). 2018 Apr 30     [PubMed]
Rose T,Schneider U,Bertolo M,Klotsche J,Casteleyn V,Biesen R,Burmester GR,Hiepe F, Observational study and brief analysis of diagnostic criteria in relapsing polychondritis. Rheumatology international. 2018 Aug 6     [PubMed]
Behar JV,Choi YW,Hartman TA,Allen NB,McAdams HP, Relapsing polychondritis affecting the lower respiratory tract. AJR. American journal of roentgenology. 2002 Jan     [PubMed]
Lekpa FK,Chevalier X, Refractory relapsing polychondritis: challenges and solutions. Open access rheumatology : research and reviews. 2018     [PubMed]
Dion J,Leroux G,Mouthon L,Piette JC,Costedoat-Chalumeau N, [Relapsing polychondritis: What's new in 2017?] La Revue de medecine interne. 2018 Jun     [PubMed]
Meshkov AD,Novikov PI,Zhilyaev EV,Ilevsky IDJ,Moiseev SV, Tofacitinib in steroid-dependent relapsing polychondritis. Annals of the rheumatic diseases. 2018 May 3     [PubMed]
Moulis G,Pugnet G,Costedoat-Chalumeau N,Mathian A,Leroux G,Boutémy J,Espitia O,Bouillet L,Berthier S,Gaultier JB,Jeandel PY,Konaté A,Mékinian A,Solau-Gervais E,Terrier B,Wendling D,Andry F,Garnier C,Cathébras P,Arnaud L,Palmaro A,Cacoub P,Amoura Z,Piette JC,Arlet P,Lapeyre-Mestre M,Sailler L, Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the rheumatic diseases. 2018 Aug     [PubMed]
Sharma A,Law AD,Bambery P,Sagar V,Wanchu A,Dhir V,Vijayvergiya R,Sharma K,Gupta A,Panda NK,Singh S, Relapsing polychondritis: clinical presentations, disease activity and outcomes. Orphanet journal of rare diseases. 2014 Dec 20     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Optometry-Clinical Science. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Optometry-Clinical Science, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Optometry-Clinical Science, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Optometry-Clinical Science. When it is time for the Optometry-Clinical Science board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Optometry-Clinical Science.